Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
Atrial Fibrillation
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.

Trial Locations (31)

1309

Sofia

1750

Sofia

4000

Plovdiv

9010

Varna

13005

Marseille

13353

Berlin

20099

Hamburg

31059

Toulouse

34662

Istanbul

34846

Istanbul

53105

Bonn

55139

Samsun

65025

Odesa

75571

Paris

83045

Donetsk

88000

Uzhhorod

94010

Créteil

115093

Moscow

117997

Moscow

121552

Moscow

194156

Saint Petersburg

410039

Saratov

04289

Leipzig

31-121

Krakow

91-347

Lodz

20-954

Lublin

02-005

Warsaw

02-507

Warsaw

50-420

Wroclaw

Unknown

Istanbul

03680

Kiev

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY

NCT01839357 - Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter | Biotech Hunter | Biotech Hunter